Single-dose safety study of SHR-7012 in healthy adults
Part of Skin clinical trials.
This study tests a single dose of a new drug called SHR-7012 in healthy volunteers to check if it is safe and how the body handles it. It is a first-in-human trial, so participants will be closely monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 55 years
- Body mass index (BMI) between 19 and 26 kg/m²
- Weight at least 50 kg for men or 45 kg for women
- No significant current or past medical conditions, and no active infections
- Not pregnant or breastfeeding, and using effective contraception if relevant
- No recent vaccinations, medications, or participation in other trials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This study tests a new investigational drug called ISH0613 in healthy volunteers to see if it is safe and how the body processes it. It is the first time this drug is given to humans.
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
This study tests a single dose of an investigational drug called SYH2085 in healthy volunteers to check for side effects, how the body processes the drug, and what happens at different doses. If you qualify, you will help doctors understand if the drug is safe before testing it in patients.
This early-stage study tests a new experimental drug called LG-0317 in healthy volunteers to see if it is safe and how the body processes it. If you are healthy and meet the basic requirements, this trial may help advance a new treatment option.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.